---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000107"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:21:45.217230+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement

## Summary
- Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.
- Cash, equivalents & marketable securities $162.1M as of June 30; pro forma for July placement total $374M.
- Phase 3 PROSERA study of seralutinib in PAH expected to start in Q3 2023; primary endpoint 6MWD at week 24.
- Additional TORREY open-label extension data expected in Q4 2023 or Q1 2024.
- July private placement raised ~$212M gross from sale of shares and warrants to institutional investors.

## SEC filing metadata
- accession: 0001728117-23-000107
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/0001728117-23-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/goss-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000107
- JSON: https://secwatch.observer/filing/0001728117-23-000107.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000107.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share, EPS $0.45 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share
  - EPS: $0.45 per share
  - Result: reported results
  source text: On August 8, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/0001728117-23-000107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.